Kornimate/medical-research-clean huggingface dataset:
auricular acupressure (aa) for overweight/obese adolescent and young polycystic ovary syndrome ( pcos)

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of this trial is to investigate the effect and safety of auricular acupressure on adolescent and young women with pcos. subjects will be randomly assigned in to two arms: auricular acupressure arm and placebo auricular acupressure, both arms will be treated for three months. body mass index, oral glucose tolerance test, hormonal profile and metabolic profile will be determined.


Eligibility criteria:
inclusion criteria: * women aged between 12 and 25 years. * diagnosis of pcos according to the modified rotterdam criteria. * 2 years after menarche. * body mass index (bmi) equal to or greater than 23 kg/m\*m. exclusion criteria: * administration of other medications known to affect reproductive function or metabolism within the past three months, including oral contraceptives, gonadotropin-releasing hormone (gnrh) agonists and antagonists, anti androgens, gonadotropins, anti-obesity drugs, chinese herbal medicines, anti diabetic drugs such as metformin and thiazolidinediones, somatostatin, diazoxide, and calcium channel blockers. * patients with other endocrine disorders including 21-hydroxylase deficiency, hyperprolactinemia, uncorrected thyroid disease, suspected cushing's syndrome. * patients with known severe organ dysfunction or mental illness.
teriflunomide's therapeutic mechanisms of action in patients with relapsing remitting multiple sclerosis.

Conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS

Summary: the purpose of this research is to characterize the effect of teriflunomide on the activation of b-cells, as well as its capacity to modify b-cell cytokine secretion. the in-vitro identified effects of teriflunomide on the expression of b-cell activation markers, costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then be confirmed in a cohort of relapsing remitting multiple sclerosis (rrms) patients treated with this medication.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of rrms according to mcdonald's diagnostic criteria, * age 18-55, * an extended disability status score (edss) of 1.5-5.5. exclusion criteria: - previous treatment with dmt.
safety and efficacy of sr121463b in patients with syndrome of inappropriate antidiuretic hormone secretion

Conditions: Inappropriate ADH Syndrome; Hyponatremia

Summary: to determine the long-term safety and tolerability of sr121463b in patients with syndrome of inappropriate antidiuretic secretion (siadh). to assess the long-term efficacy of sr121463b in maintaining normal levels of serum sodium in patients with siadh. long term safety is evaluated further in an open label extension study with flexible doses of satavaptan.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18 years and higher. * siadh (the diagnosis of siadh is based on several criteria including true serum hypoosmolality, inappropriate urinary osmolality, clinical euvolemia, elevated urinary sodium excretion while on normal salt and water intake, and normal renal, adrenal, and thyroid functions: drug induced siadh will be limited to carbamazepine or derivatives and antidepressants in patients in whom these drugs cannot be discontinued or easily replaced by other drugs) * serum sodium between 115 and 132 mmol/l (at least two consecutive serum sodium levels of at least 24 hours apart, from day -6 to day -1); for sodium levels between 125 and 132 mmol/l, the spontaneous serum sodium increase between the two assessments on day -1 should be \< 4 mmol/l * urinary osmolality \>200mosm/kg h2o * urinary sodium \> 30 mmol/l exclusion criteria: * patients with acute postoperative siadh * presence of dilutional hyponatremia in hypervolemic states such as congestive heart failure and liver disease with ascites * presence of signs of hypovolemia (e.g., orthostatic hypotension, increased serum urea nitrogen, increased serum albumin, increased hematocrit, ...) * administration of other v2 receptor antagonists or demeclocycline or lithium within one month, thiazides diuretics or spironolactone within 15 days, and urea or loop diuretics within two days prior to study drug administration * patients with known treated or untreated adrenal deficiency * presence of untreated hypothyroidism * presence of uncontrolled diabetes with fasting glycemia \> 200 mg/dl (\> 11.09 mmol/l) * presence of clinical and/or electrocardiographical signs of acute myocardial infarction or acute ischemia, or any other clinically significant abnormality according to the investigator on a 12 lead ecg recording * administration of inducers of cyp3a4 (phenytoin, rifampin, saint john's wort) or potent and moderate inhibitor so cyp3a4within two weeks prior to study drug administration * inadequate hematological, renal and hepatic functions; hemoglobin (hb) \ 175 µmol/l (or clearance of creatine \ 2x upper limit of normal * qtcb \> 500 ms * serum potassium \> 5 mmol/l

Keywords: inappropriate adh syndrome hyponatremia
caregiving during crisis

Conditions: Caregiver Stress Syndrome

Summary: this study will test a prototype pandemic caregiver training and education course designed for caregivers of persons living with dementia (plwd). participants will be randomized to take the course immediately or to take the course after completion of an 8-week waiting period.

family caregivers, the backbone of care for the upwards of 7 million community-dwelling individuals living with alzheimer's disease in the u.s., provide at least 85% of the care these individuals receive, at some risk to their own well-being, and are instrumental in navigating healthcare systems. without their care, it is almost certain that persons living with dementia (plwd) would have much higher rates of acute and emergency care use than their age-matched peers, perilous venues for them in the best of times, potentially deadly during this pandemic. with coronavirus disease 2019 (covid-19) restrictions, the amount of care they provide and the expertise needed to provide the care will increase. typically, caregivers are strangers in healthcare and pandemic landscapes, but they are now called on to enact home care and safety measures and navigate an intricate, complex, and opaque system without the benefit of a compass or a translator, and largely without understanding their role in or having the skills for navigating the system. a variety of interventions have demonstrated benefit in enhancing caregivers' caregiving capacities, with resulting positive outcomes for both caregivers and care recipients. only a few of these useful interventions, tele-savvy among them, have employed distance delivery means, thus enabling rural caregivers and others precluded by circumstance from attending in-person programs to take part in the intervention programs. the study will assess a psychoeducational intervention for dementia caregivers. participating caregivers will be randomized to immediately enroll in the study intervention or to be in a waitlist group that will begin the intervention 8 weeks later. participants will complete interviews at baseline and after the 8-week study period.

Eligibility criteria:
inclusion criteria: * providing care for a family member or friend with a confirmed diagnosis of dementia * lives in the community * co-resides with the plwd * is the main caregiver for the plwd * has access to a computer with internet service * can read and understand english exclusion criteria: * none

Keywords: dementia family caregiver online education
clinical retrospective study analysis of postoperative complications following hepatectomy

Conditions: Liver Failure; Liver Dysfunction

Summary: hepatectomy is a crucial surgical method for treating liver diseases such as liver cancer, hepatic hemangiomas, and biliary stones. although hepatectomy has achieved significant therapeutic effects, postoperative complications remain an inevitable issue. complications following hepatectomy include liver failure, hepatic vascular thrombosis, wound infection at the hepatic incision, and bile leakage, among others. these complications pose a serious threat to patients' health and life, and also increase the waste of medical resources and the cost of treatment. currently, research on postoperative complications of hepatectomy mainly focuses on small sample studies from a single center, and most studies only focus on a specific complication, lacking comprehensive and systematic analysis. therefore, it is necessary to conduct a retrospective study analysis of complications related to hepatectomy to more comprehensively and objectively understand the incidence, risk factors, prevention, and treatment of postoperative complications, providing clinical doctors with more scientific treatment plans and guidance.


Eligibility criteria:
inclusion criteria: * 1. patients aged 18-80 years 2.patients who underwent liver resection surgery at the participating centers exclusion criteria: * exclusion criteria are as follows: 1. prior cancer treatments such as transarterial chemoembolization, ablation, or targeted therapy. 2. repeat liver resection surgeries. 3. presence of other malignancies. 4. concurrent end-stage diseases including active infections, respiratory failure, decompensated heart failure, and autoimmune disease exacerbations. 5. inadequate clinical data availability in medical records.

Keywords: hepatectomy liver failure post-hepatectomy liver failure
minimally-invasive assessment of cardiac output in severe preeclampsia

Conditions: Preeclampsia

Summary: severe preeclampsia often presents with uncontrolled hypertension and therefore requires close monitoring of blood pressure and cardiac performance. the purpose of the study is to compare two methods of measuring the performance of the heart in pregnant women: one by ultrasound of the heart, the other by assessing the pulse generated in the blood vessel of the wrist. we hope that the method using pulse analysis will be as effective as ultrasound, which is labour intensive and operator dependant.

severe preeclampsia often presents with uncontrolled hypertension, which requires close monitoring of blood pressure and cardiac output. it will be very useful to know the cardiac output in this patient population, because it will guide the choice of antihypertensive drugs and measure their effect on cardiac output. traditionally pulmonary artery catheters were used to measure cardiac output. there are numerous problems with using this method in severe preeclampsia. these include technical difficulty inserting the catheter in an awake, edematous pregnant patient, potentially causing a pneumothorax, damaging the carotid artery or insertion site infection. there is also an increased risk for cardiac arrhythmias. apart from the risks, the accuracy of the thermodilution measurements can be influenced by factors such as timing of the injection within the respiratory cycle, temperature of the injectate, speed of injection, and placement of the catheter. a readily available, accurate non-invasive cardiac output measurement technique, that will provide reliable data with fewer risks, is needed. doppler ultrasound (trans thoracic echocardiography) is the gold standard for measuring cardiac output non-invasively in pregnant patients. unfortunately the method is operator dependant, not continuous and not always available when needed most. recently a device called the flotrac has been introduced that measures cardiac output minimally invasively. attached to an arterial line it measures cardiac output every 20 seconds via arterial waveform analysis. the standard of care for measuring blood pressure in severe preeclampsia requires the placement of an intra-arterial line. this group of patients is therefore ideal for measuring cardiac output with the flotrac, especially since powerful intravenous anti-hypertensives are used to control blood pressure. our hypothesis is that the flotrac will be comparable to doppler ultrasound for measuring cardiac output in severely preeclamptic patients.

Eligibility criteria:
inclusion criteria: * severe preeclampsia * arterial line required * candidates for magnesium sulfate, labetalol or hydrazine exclusion criteria: * preexisting cardiac disease

Keywords: preeclampsia hemodynamic monitoring
evaluation of open-face maxillary complete denture for patients with prominent premaxilla

Conditions: Edentulous Jaw

Summary: the aim of the present study was to evaluate open faced maxillary complete denture with soft acryl resin wing versus conventional heat cured maxillary complete denture regarding the retention and patient satisfaction.


Eligibility criteria:
inclusion criteria: * completely edentulous male patients. * patients having had no previous complete dentures * patients with well-developed edentulous ridge with proclined premaxilla covered with healthy firm mucosa * patients with normal angle class 1 maxillomandibular relationship exclusion criteria: * patients with resorbed ridges * patients with xerostomia and patients undertaking medications that affect salivary flow (e.g., diuretics). similarly, patients with systemic diseases that may affect the amount or consistency of saliva (e.g., uncontrolled diabetes mellitus).

Keywords: prominent premaxilla
evaluation of long-term safety and effectiveness of fostamatinib in the treatment of rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * patients who have successfully completed a qualifying study (d4300c00001, d4300c00002, d4300c00003 or d4300c00004) with fostamatinib * patients who have participated in a qualifying study and who have been classified as non-responders due to pre-defined lack of efficacy at week 12 (d4300c00001, d4300c00002, d4300c00003). exclusion criteria: * premature withdrawal from the qualifying study (d4300c00001, d4300c00002, d4300c00003 and d4300c00004) * females who are pregnant or breast feeding * poorly controlled hypertension * significant liver function test abnormalities or physical symptoms of hepatotoxicity * significant infection * gastrointestinal intolerance * cancer

Keywords: rheumatoid arthritis oskira fostamatinib
bioequivalence study of nimesulide 100 mg tablets

Conditions: Pain

Summary: the objective of this study was to confirm if two formulations of nimesulide tablets are bioequivalent. test product was eskaflam® (nimesulide 100 mg tablets; glaxosmithkline) and reference product mesulid® (nimesulide 100 mg tablets; syntex for productos roche). the single dosage was one tablet. the study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions. the population was composed of 28 healthy volunteers, both genders, adults between 18-40 years. the comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.


Eligibility criteria:
inclusion criteria: free will participation according to mexican regulation, helsinki declaration, and good clinical practice. healthy, between 18 and 40 years. body mass index between 19 and 27 in good health by complete medical history and laboratory tests. blood pressure 130-90/ 90-60 mm hg; heart rate 55-100 beat per minute, respiratory rate 14-20 movements per minute. laboratory tests +/- 10% of normal interval (blood cytology, blood chemistry 27 elements, hepatitis b and c antigens, hiv, urinalysis, anti-doping, pregnancy, electrocardiogram) - exclusion criteria: alteration of vital signs not complying with inclusion criteria history of cardiovascular, kidney, hepatic, muscular, metabolic, gastrointestinal (including constipation), neurologic, endocrine, hematopoietic (any kind of anemia), asthma, mental or organic disease. those suffering from muscular trauma 21 days before the beginning of the study. requirement of any kind of medication during the course of the study, except study medication. history of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer. exposure to medications known as inducers or inhibitors of hepatic enzymes or administration of potentially toxic medication in the 30 days before the study beginning. administration of any medication in the 14 days or 5 half-lives (whatever longer) previous to the beginning of the study. hospitalization for any cause in the seven months before the beginning of the study. administration of investigational drugs in the 60 days before the study. allergy to any antibiotic or non-steroidal anti-inflammatory analgesic. alcohol ingestion or intake of beverages containing xanthines (coffee, tea, cocoa, chocolate, mate, cola drinks) or ingestion of charcoal grilled food or grapefruit or orange juice in the 72 hours before the hospitalization or tobacco smoking in the 72 hours before the beginning of the study. blood donation or loss =\> 450 ml in the 60 days before the beginning of the study. history of drug or alcohol abuse. positive pregnancy test. special diet requirement, for instance vegetarian diet. inability to understand nature, aims, and possible consequences of the study. evidence of non-cooperative attitude during the study. -

Keywords: bioequivalence nimesulide pharmacokinetics mexico
brain activation in response to appetitive cues pre- and post- bariatric surgery

Conditions: Obesity

Summary: utilizing fmri, this study will examine changes in bold signal as a proxy measure of brain activation in response to highly palatable (high energy density \[kcal/g\]), less palatable and non-food stimuli in severely obese women pre, 1 month post and 3 months post undergoing bariatric surgery (in surgery patients) and at equivalent times for control groups in fed and fasted conditions at each time point. two surgical groups: (i) laparoscopic roux-en-y gastric bypass (rygb) and (ii) gastric banding (gb) will be compared with two control groups: (i)those enrolled on a 3-month formula weight loss program or (ii) those who qualify, but do not undergo bariatric surgery, and receive no weight loss treatment.


Eligibility criteria:
inclusion criteria: * age \> 18 and \< 65 years * bmi \> 40 and \< 50kg/m2 * right handed * good comprehension of english exclusion criteria: * \> 5% weight fluctuation in the past 3 months * presence of disease (including diabetes) * pregnancy, lactation or planning to become pregnant in next 18mon * smoking, or or recent (within past 12 month) smoking cessation * consumption of \> 3 alcoholic beverages per day * left handed

Keywords: roux-en-y bariatric surgery, gastric banding, fmri, food cues
the long-term safety and efficacy of cdp6038 (olokizumab) with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the long-term safety and tolerability of cdp6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis (ra) who completed study ra0083 \[nct01463059\].

male and female subjects were randomized in a multi-center, open-label, follow-up study to assess the long-term safety and efficacy of a subcutaneous dose of 120 mg cdp6038 (olokizumab), every 2 weeks (q2w), for the treatment of active ra.

Eligibility criteria:
inclusion criteria: * completed the ra0083 \[nct01463059\] study (week 12 visit) * must have maintained their stable dose (and route) of methotrexate (mtx) between 6 to 16 mg/week in japan or 7.5 to 20 mg/week in korea and taiwan in ra0083 \[nct01463059\], and plan to maintain this same dose and route of administration for at least 12 weeks * female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception exclusion criteria: * have an ongoing sae from the ra0083 \[nct01463059\] study * female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks * have evidence of active or latent tuberculosis (tb) * subject is receiving any biologic response modifier or synthetic disease-modifying antirheumatic drug (dmard) other than mtx * subject has planned surgery during the first 12 weeks of the study * subjects who tested positive for hepatitis b core antibody (hbcab) and/or hepatitis b surface antibody (hbsab) at screening in ra0083 \[nct01463059\] and who subsequently test positive for hepatitis b virus deoxyribonucleic acid (hbv dna) at week 12 of ra0083 \[nct01463059\]

Keywords: rheumatoid arthritis monoclonal antibody interleukin-6 olokizumab cdp6038
the self-compassion online - preventing depression trial

Conditions: Depression

Summary: purpose: depression affects 12.6% of canadians at some point in their life. depression is associated with staggering personal and economic costs. there are several treatments that have been shown to treat episodes of depression when they occur. unfortunately, more than half who respond to these treatments go on to re-experience an episode of depression. even with psychological and pharmacological interventions designed to prevent future episodes, relapse and recurrence of the disorder remain alarmingly high. a patient-focused and self-directed intervention that harnesses the effects of an eastern-influenced concept, called self-compassion, has shown tremendous promise in treating acute depression. self-compassion is being moved by one's own suffering, and a desire to alleviate such suffering. objectives: in the proposed project, the investigators will examine whether a self-compassion intervention is effective in preventing relapse/recurrence of depression over a 12-month period among people who are at high risk for relapse. the investigators will also examine whether the intervention works to prevent depression by increasing the innate ability to bounce back from stress, a concept known as resilience. methodology: 120 participants with a history of depression will be randomly assigned to the self-compassion intervention or a self-assessment reflection condition, and their respective relapse rates will be examined over a period of 12 months. importance to research: this will be the first study to examine the effects of self-compassion as a preventive intervention for depression. impact on health: if successful, this new intervention can be used by thousands of people in saskatchewan and canada who are at risk for depression relapse.


Eligibility criteria:
inclusion criteria: * to be eligible to participate in the study, participants must be: a) 18 years old or older; b) have experienced at least one episode of depression; and c) exhibit elevated residual symptoms of depression-as indicated by a score of 5 or more on the patient health questionnaire-9 (phq-9; kroenke, spitzer, \& williams, 2001). as the majority of people experience both depression and anxiety symptoms concurrently, participants experiencing elevated anxiety symptoms will not be excluded from the study. exclusion criteria: * participants will be excluded from the study if they indicate: a) a current diagnosis mdd, substance use disorder, psychosis, or mania in accordance with the diagnostic and statistical manual of mental disorders-5 (dsm-5; american psychiatric association, 2013); b) the presence of major health conditions (e.g., cardiovascular diseases, cancer, hypothyroidism, etc.); and c) currently undergoing psychological or pharmacological treatment at the time of recruitment